Pancreatic Cancer Research

ResearcherUniversity of Campania "Luigi Vanvitelli"Active in the last 2 years

Ferdinando De Vita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7654-7470; OpenAlex author ID A5004962478, A5009130863. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
74
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 3 papers

Papers 16

  1. Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41392-025-02546-8↗
  2. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  3. Complete and Persistent Response to Immunotherapy in Highly Pretreated MSS TMB-High Pancreatic Adenocarcinoma: A Case Report and Literature Review. Last author DOI 10.3390/ijms27135722↗
  4. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  5. Identification of Tissue miRNA Signatures for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16040824↗
  6. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  7. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  8. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients. Co-author DOI 10.3390/cells11213340↗
  9. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  10. Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. Co-author DOI 10.3389/fonc.2021.695627↗
  11. Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. Co-author DOI 10.3390/cancers13112797↗
  12. Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. Last author DOI 10.3390/ijms21082814↗
  13. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Last author DOI 10.1007/s12032-019-1306-9↗
  14. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propen… Last author DOI 10.1155/2018/2373868↗
  15. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. Co-author DOI 10.1186/s12885-016-2671-9↗
  16. Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and liter… Co-author DOI 10.3892/ol.2016.5279↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chiara Carmen Miceli · 3 shared papers, 2024–2026 · strength 0.65
  2. Fortunato Ciardiello · 5 shared papers, 2016–2026 · strength 0.64
  3. Guido Giordano · 5 shared papers, 2016–2026 · strength 0.62
  4. Elisa Giommoni · 4 shared papers, 2022–2026 · strength 0.61
  5. Davide Melisi · 4 shared papers, 2021–2026 · strength 0.57
  6. Luca Pompella · 5 shared papers, 2018–2024 · strength 0.56
  7. Michèle Milella · 4 shared papers, 2021–2024 · strength 0.50
  8. Letizia Procaccio · 3 shared papers, 2023–2026 · strength 0.48
  9. Sara Lonardi · 3 shared papers, 2023–2026 · strength 0.48
  10. Francesca Bergamo · 3 shared papers, 2023–2026 · strength 0.48
  11. Alberto Zaniboni · 3 shared papers, 2023–2026 · strength 0.48
  12. Enrico Vasile · 3 shared papers, 2022–2026 · strength 0.47
  13. Angelica Petrillo · 5 shared papers, 2016–2021 · strength 0.46
  14. Giampaolo Tortora · 3 shared papers, 2021–2026 · strength 0.44
  15. Matteo Landriscina · 2 shared papers, 2024–2026 · strength 0.35
  16. Roberto Bianco · 2 shared papers, 2024–2026 · strength 0.35
  17. Annalisa Pappalardo · 3 shared papers, 2019–2021 · strength 0.34
  18. Mario Scartozzi · 2 shared papers, 2023–2026 · strength 0.33
  19. Andrea Pretta · 2 shared papers, 2023–2026 · strength 0.33
  20. Simona Casalino · 2 shared papers, 2023–2026 · strength 0.33
  21. Michele Orditura · 4 shared papers, 2016–2020 · strength 0.31
  22. Mariacristina Di Marco · 2 shared papers, 2021–2026 · strength 0.29
  23. Monica Niger · 2 shared papers, 2021–2026 · strength 0.29
  24. Vanja Vaccaro · 2 shared papers, 2023–2024 · strength 0.28
  25. Rosaria Benedetti · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.